Product Information

TROKENDI XR 100 MG CAPSULE is a brand product labeled by Supernus Pharmaceuticals Inc., priced at $34.4176 per EA under NDC 17772010330. Its NADAC has been published 469 times since Nov 29, 2017.

FDA first approved this application on Aug 16, 2013. Its Orange Book therapeutic-equivalence code is AB1 — FDA rates it therapeutically equivalent to (substitutable for) its reference product.

The High Outlier badge above means this manufacturer's average price in the topiramate market falls above Q3 + 1.5·IQR across all competing manufacturers. We only apply this flag in markets with four or more competitors. Full definition: glossary → outlier.

TROKENDI XR 100 MG CAPSULE

topiramate
$34.4176per EA
High Outlier

Strength

100 mg/1

NDC

17772010330

Classification

Brand

Dosage Form

CAPSULE, EXTENDED RELEASE

Route

ORAL

Effective Date

11/18/2026

Active Ingredients

TOPIRAMATE

Approval Type

New Drug (NDA)

FDA Application

NDA201635

FDA Approved

8/16/2013

TE Code

AB1

On Market Since

8/16/2013

Pharmacological Classes

Cytochrome P450 2C19 Inhibitors
Cytochrome P450 3A4 Inducers
Decreased Central Nervous System Disorganized Electrical Activity

Price Statistics

The NADAC for TROKENDI XR 100 MG CAPSULE has been published 469 times since Nov 29, 2017, and over the history we have for it it has risen 69.5%. The table below summarizes its recorded NADAC range and movement.

Current price$34.4176 per EA
All-time high$34.4376 (Nov 11, 2026)
All-time low$20.3081 (Nov 29, 2017)
52-week high$34.4376
52-week low$31.7161
Median price$28.7769
Average price$27.7732
Largest weekly change+8.0% (Jan 9, 2019)
Weeks tracked469
Tracking sinceNov 29, 2017

Price History

1W

-0.1%

1M

-0.1%

3M

-0.1%

6M

+7.9%

1Y

+7.2%

3Y

+13.6%

5Y

+26.8%

All

+69.5%

Generic Alternatives

The matcher finds 3 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 82% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.

Continue researching this drug

Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.

Frequently asked questions

What is the NADAC price of TROKENDI XR 100 MG CAPSULE?

The current National Average Drug Acquisition Cost (NADAC) for TROKENDI XR 100 MG CAPSULE, manufactured by Supernus Pharmaceuticals Inc., is $34.4176 per EA (NDC 17772010330), effective Nov 18, 2026.

How has the price of TROKENDI XR 100 MG CAPSULE changed over time?

Over the history we have for it, the NADAC for TROKENDI XR 100 MG CAPSULE has risen 69.5%. It has been tracked across 469 weekly CMS publications since Nov 29, 2017.

What are the highest and lowest recorded NADAC prices for TROKENDI XR 100 MG CAPSULE?

Since Nov 29, 2017, the NADAC for TROKENDI XR 100 MG CAPSULE has ranged from a low of $20.3081 (Nov 29, 2017) to a high of $34.4376 (Nov 11, 2026), with a median of $28.7769 per EA.

Are there cheaper alternatives to TROKENDI XR 100 MG CAPSULE?

Yes. 3 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, TOPIRAMATE ER 100 MG SPRINK CAP, is $6.0614 per EA — about 82% below TROKENDI XR 100 MG CAPSULE.

Who manufactures TROKENDI XR 100 MG CAPSULE?

TROKENDI XR 100 MG CAPSULE (NDC 17772010330) is labeled by Supernus Pharmaceuticals Inc., and CMS classifies it as a brand product.